Zealand Pharma AS (OCSE:ZEAL)
kr 730 0 (0%) Market Cap: 51.57 Bil Enterprise Value: 43.49 Bil PE Ratio: 0 PB Ratio: 5.83 GF Score: 67/100

Zealand Pharma A/S Corporate Call Transcript

Sep 30, 2022 / 12:00PM GMT
Release Date Price: kr173.8 (+28.46%)
Operator

Good day, and thank you for standing by. Welcome to the conference call to discuss positive results from Phase III trial of Glepaglutide in patients with Short Bowel Syndrome. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Anna Krassowska. Please go ahead.

Anna Krassowska;S;VP of IR;Corporate Communications
Zealand Pharma A

/-&

Thank you. Welcome, everyone, and thank you for joining us today. I'm Anna Krassowska, Vice President of Investor Relations and Corporate Communications at Zealand. With me today to discuss Zealand's top line results for the Phase III EASE 1 trial of Glepaglutide in patients with Short Bowel Syndrome are Adam Steensberg, Zealand's President and Chief Executive Officer; and David Kendall, Zealand's Chief Medical Officer.

You can find the related company announcement on our website at zealandpharma.com. I would like to point out that we will be making forward

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot